Steven E. Finkelstein, MD, FACRO

Associated Medical Professionals

Syracuse, New York

Steven E. Finkelstein, MD, FACRO, is the Director of the Center of Advanced Radiation Excellence, and Director of Radiation Oncology Research for Associated Medical Professionals in Syracuse, New York. His interests include the research of a variety of cancers, busting radiation driven, and personalized systemic therapy. He holds three international patents in the field of cutting edge technologies.

Dr. Finkelstein received his medical degree from the University of Michigan Medical School, graduating cum laude eruditions causa. He then joined the National Cancer Institute, National Institutes of Health as Clinical Associate. He completed both Surgical Oncology Fellowship as well as Clinical Immunotherapy Fellowship, and an additional radiation oncology residency.

He served a residency in General Surgery at Washington University in Saint Louis, Missouri, Dr. Finkelstein also served fellowships in Biologic Immunotherapy, Clinical Cancer, and Surgical Oncology at the Surgery Branch of the National Cancer Institute in Bethesda, Maryland. He is a member of the American College of Radiation Oncology, the American Medical Association, the American Society of Clinical Oncology, the American Society for Therapeutic Radiology and Oncology, the Radiological Society of North America, and the Radiation Therapy Oncology Group.

He has served as a Co-Chair on the NRG Immunotherapy Committee, Co-Chair of the 2018-2019 ACRO Scientific Program Committee, and Chair of the SWOG Radiation STG Committee. He currently serves on the Board of Chancellors for ACRO. Dr. Finkelstein has also served as National Director of Translational Research Consortium (TRC), the cutting-edge therapy arm of 21st Century Oncology in Scottsdale, Arizona. Inspired by his grandmother, a cancer patient, he became a dedicated cancer surgeon who found that radiation therapy could sometimes do for his patients what surgery could not.

Disclosures:

Talks by Steven E. Finkelstein, MD, FACRO

Metastasis-Directed Therapy: Radiation Oncology Updates and Perspective

Posted by Steven E. Finkelstein, MD, FACRO | Oct 2020

Steven E. Finkelstein, MD, FACRO, a radiation oncologist with Florida Cancer Affiliates in Panama City, Florida, discusses metastasis-directed therapy (MDT) as a potential treatment option for oligometastatic prostate cancer. He reviews typical management of metastatic cancer and describes how MDT can minimize the toxicity of systemic therapy, then addresses future treatment options with stereotactic ablative radiotherapy (SABR). Radiation and other local therapies are used for palliation of metastases but can also alter the course of tumor development. Dr. Finkelstein explains that MDT can be particularly beneficial in oligometastatic prostate cancer if the metastases are at a point where both the primary tumor and metastases can be treated together and likely cured. Lastly, he concludes that MDT via SABR could be employed concurrently with other treatments such as androgen deprivation therapy (ADT), chemotherapies, and radiopharmaceuticals, and that further research is necessary.

New Approaches to Combining Brachytherapy with Immunotherapy

Posted by Steven E. Finkelstein, MD, FACRO | Jun 2020

Steven E. Finkelstein, MD, FACRO, a radiation oncologist with Florida Cancer Affiliates in Panama City, Florida, discusses the growing field of brachytherapy-driven immunotherapy and its potential role in prostate cancer treatment. He goes on to discuss the mechanisms behind radiation-induced tumor death, the growing evidence behind the immunostimulatory effects of radiation, and a patent describing a radiation-based applicator and potential method for administering immunotherapy agents to cancerous tissue.

Safely Managing a Radiation Oncology Clinic in the Age of COVID-19

Posted by Steven E. Finkelstein, MD, FACRO | Apr 2020

Steven E. Finkelstein, MD, FACRO, a radiation oncologist with Florida Cancer Affiliates in Panama City, Florida, provides guidance on how to safely manage a radiation oncology clinic during the COVID-19 crisis. He explains that it is important to screen patients for COVID-19 symptoms before treatments, and emphasizes that staff must be trained in how to safely work with potentially infected individuals. Noting that every practice will have to plan differently depending on its resources and the population it serves, Dr. Finkelstein also discusses how practices might minimize the number of patients seen, i.e. by deferring radiation treatments for prostate cancer in favor of increased duration of neoadjuvant ADT or active surveillance when appropriate. He observes that while alternatives to traditional radiation oncology like seed implantation could minimize clinic visits, many practices currently lack the resources to implement brachytherapy.

Brachytherapy/Caesium

Posted by Steven E. Finkelstein, MD, FACRO | Jun 2019

Steven E. Finkelstein, MD, FACRO, discusses the increasing prevalence of brachytherapy as an option for prostate cancer patients in need of radiation therapy, specifically in the recurrent space. Additionally, he addresses the limitations of the technique and the lack of studies directly comparing brachytherapy to other options.

Emerging Indications for a Novel Absorbable Hydrogel Spacer: A 2018 Review